Regulatory T-cell Responsiveness Predicts Risk of Cancer Relapse
By LabMedica International staff writers Posted on 15 Jul 2019 |
Image: A scanning electron micrograph (SEM) of a human T-cell from the immune system of a healthy donor (Photo courtesy of [U.S.] NIAID).
The risk of future breast cancer relapse can be predicted by analyzing the signaling responsiveness of peripheral blood Treg II cells (CD45RA−FOXP3hi Treg cells) to immunosuppressive T helper type 1 (TH1) and T helper type 2 (TH2) cytokines.
Th1 helper cells lead to an increased cell-mediated response, typically against intracellular bacteria and protozoa. Th2 helper cells lead to a humoral immune response, typically against extracellular parasites including helminths.
The regulatory T-cells (Tregs) are a subpopulation of T-cells that modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease. Tregs are immunosuppressive and generally suppress or downregulate induction and proliferation of effector T-cells. Tregs express the biomarkers CD4, FOXP3, and CD25 and are thought to be derived from the same lineage as naïve CD4 cells. Because effector T-cells also express CD4 and CD25, Tregs are very hard to effectively discern from effector CD4+, making them difficult to study.
Investigators at City of Hope (Duarte, CA, USA) studied the origin of breast cancer- related intratumoral Treg cells and their relationship with peripheral blood Treg cells. In this study, the investigators evaluated data on 40 breast cancer patients who had been monitored for a median of four years. Results were validated in a separate cohort of 38 additional breast cancer patients to create a benchmark that could be used to predict whether a breast cancer patient would be likely to relapse within a short span of years.
“This is the first success linking a solid tumor with blood biomarkers - an indicator of whether a patient will remain in remission,” said senior author Dr. Peter P. Lee, professor of cancer immunotherapeutics at City of Hope. “When patients are first diagnosed with cancer, it is important to identify those at higher risk for relapse for more aggressive treatments and monitoring. Staging and new tests based on genomics analysis of the tumor are currently available for risk stratification. However, a predictive blood test would be even more attractive but is not yet available. We are trying to change the status quo. Knowing the chance of cancer relapse will inform doctors how aggressive a particular patient’s cancer treatment should be.”
The breast cancer relapse study was published in the July 8, 2019, online edition of the journal Nature Immunology.
Related Links:
City of Hope
Th1 helper cells lead to an increased cell-mediated response, typically against intracellular bacteria and protozoa. Th2 helper cells lead to a humoral immune response, typically against extracellular parasites including helminths.
The regulatory T-cells (Tregs) are a subpopulation of T-cells that modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease. Tregs are immunosuppressive and generally suppress or downregulate induction and proliferation of effector T-cells. Tregs express the biomarkers CD4, FOXP3, and CD25 and are thought to be derived from the same lineage as naïve CD4 cells. Because effector T-cells also express CD4 and CD25, Tregs are very hard to effectively discern from effector CD4+, making them difficult to study.
Investigators at City of Hope (Duarte, CA, USA) studied the origin of breast cancer- related intratumoral Treg cells and their relationship with peripheral blood Treg cells. In this study, the investigators evaluated data on 40 breast cancer patients who had been monitored for a median of four years. Results were validated in a separate cohort of 38 additional breast cancer patients to create a benchmark that could be used to predict whether a breast cancer patient would be likely to relapse within a short span of years.
“This is the first success linking a solid tumor with blood biomarkers - an indicator of whether a patient will remain in remission,” said senior author Dr. Peter P. Lee, professor of cancer immunotherapeutics at City of Hope. “When patients are first diagnosed with cancer, it is important to identify those at higher risk for relapse for more aggressive treatments and monitoring. Staging and new tests based on genomics analysis of the tumor are currently available for risk stratification. However, a predictive blood test would be even more attractive but is not yet available. We are trying to change the status quo. Knowing the chance of cancer relapse will inform doctors how aggressive a particular patient’s cancer treatment should be.”
The breast cancer relapse study was published in the July 8, 2019, online edition of the journal Nature Immunology.
Related Links:
City of Hope
Latest Molecular Diagnostics News
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer